Patient Safety

Insurer informs members and physicians about Bextra

Published in Medical Letter on the CDC and FDA, May 22nd, 2005

Aetna (AET) announced that it is contacting more than 33,000 members who have used Bextra to inform them directly about the U.S. Food and Drug Administration's (FDA) decision to ask that Bextra be withdrawn from the market.

The FDA recently concluded the overall risk versus benefit profile for that medication is unfavorable.

In addition, Aetna will inform physicians and members that it is not paying any claims for Bextra prescriptions as of April 7, the day the FDA asked Pfizer, Inc., to withdraw the drug from the market. Aetna Pharmacy Management has instituted computer system edits that will automatically block Bextra prescriptions from being...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2005-05-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry